loadpatents
Patent applications and USPTO patent grants for Bett; Andrew J..The latest application filed is for "vaccine compositions for preventing coronavirus disease".
Patent | Date |
---|---|
Vaccine Compositions For Preventing Coronavirus Disease App 20210338804 - Parks; Christopher Lee ;   et al. | 2021-11-04 |
Hpv Vaccine App 20210252138 - Bett; Andrew J. ;   et al. | 2021-08-19 |
Rsv Rna Vaccines App 20210046173 - Ciaramella; Giuseppe ;   et al. | 2021-02-18 |
Respiratory Syncytial Virus Vaccine App 20200129608 - Ciaramella; Giuseppe ;   et al. | 2020-04-30 |
Herpes Simplex Virus Vaccine App 20200129615 - Ciaramella; Giuseppe ;   et al. | 2020-04-30 |
Herpes Simplex Virus Vaccine App 20200054737 - Ciaramella; Giuseppe ;   et al. | 2020-02-20 |
Recombinant subunit dengue virus vaccine Grant 10,137,187 - Coller , et al. November 27, 2 | 2018-11-27 |
Herpes Simplex Virus Vaccine App 20180303929 - Ciaramella; Giuseppe ;   et al. | 2018-10-25 |
Respiratory Syncytial Virus Vaccine App 20180271970 - Ciaramella; Giuseppe ;   et al. | 2018-09-27 |
Recombinant Subunit Dengue Virus Vaccine App 20160074502 - Coller; Beth-Ann Griswold ;   et al. | 2016-03-17 |
Recombinant subunit dengue virus vaccine Grant 9,198,964 - Coller , et al. December 1, 2 | 2015-12-01 |
Anti-ADDL antibodies and uses thereof Grant 8,889,138 - Acton , et al. November 18, 2 | 2014-11-18 |
Hepatitis C virus vaccine Grant 8,530,234 - Kaslow , et al. September 10, 2 | 2013-09-10 |
Recombinant Subunit Dengue Virus Vaccine App 20130216575 - Coller; Beth-Ann Griswold ;   et al. | 2013-08-22 |
Anti-ADDL antibodies and uses thereof Grant 8,383,113 - Acton , et al. February 26, 2 | 2013-02-26 |
Anti-ADDL Antibodies and Uses Thereof App 20120171224 - Acton; Paul ;   et al. | 2012-07-05 |
Hepatitis C virus vaccine Grant 8,142,794 - Emini , et al. March 27, 2 | 2012-03-27 |
Anti-ADDL antibodies and uses thereof Grant 8,128,930 - Acton , et al. March 6, 2 | 2012-03-06 |
Anti-ADDL Antibodies and Uses Thereof App 20110159013 - Acton; Paul ;   et al. | 2011-06-30 |
Anti-ADDL Antibodies and Uses Thereof App 20100272714 - Acton; Paul ;   et al. | 2010-10-28 |
Anti-addl antibodies and uses thereof Grant 7,811,563 - Acton , et al. October 12, 2 | 2010-10-12 |
Anti-ADDL antibodies and uses thereof Grant 7,780,963 - Acton , et al. August 24, 2 | 2010-08-24 |
Broadly Representative Antigen Sequences and Method for Selection App 20100183651 - Finnefrock; Adam C. ;   et al. | 2010-07-22 |
Hepatitis C Virus Vaccine App 20100129901 - Kaslow; David C. ;   et al. | 2010-05-27 |
Hepatitis C virus vaccine Grant 7,598,362 - Emini , et al. October 6, 2 | 2009-10-06 |
Hepatitis C Virus Vaccine App 20090233992 - Emini; Emilio A. ;   et al. | 2009-09-17 |
Adenovirus Serotype 26 Vectors, Nucleic Acid and Viruses Produced Thereby App 20080254059 - Bett; Andrew J. ;   et al. | 2008-10-16 |
Anti-Addl Antibodies and Uses Thereof App 20080175835 - Acton; Paul ;   et al. | 2008-07-24 |
Adenoviral Vector Compositions App 20080063656 - Emini; Emilio A. ;   et al. | 2008-03-13 |
Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications App 20070077257 - Emini; Emilio A. ;   et al. | 2007-04-05 |
Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications App 20070054395 - Emini; Emilio A. ;   et al. | 2007-03-08 |
Anti-ADDL antibodies and uses thereof App 20060228349 - Acton; Paul ;   et al. | 2006-10-12 |
Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications App 20050070017 - Emini, Emilio A. ;   et al. | 2005-03-31 |
Hepatitis c virus vaccine App 20040247615 - Emini, Emilio A ;   et al. | 2004-12-09 |
Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby App 20040191222 - Emini, Emilio A. ;   et al. | 2004-09-30 |
Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby App 20040185555 - Emini, Emilio A. ;   et al. | 2004-09-23 |
Adenovirus carrying gag gene HIV vaccine Grant 6,787,351 - Chen , et al. September 7, 2 | 2004-09-07 |
Methods for propagating adenovirus and virus produced thereby App 20040106194 - Bett, Andrew J. ;   et al. | 2004-06-03 |
Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications App 20040101957 - Emini, Emilio A. ;   et al. | 2004-05-27 |
Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications Grant 6,733,993 - Emini , et al. May 11, 2 | 2004-05-11 |
Adenovirus carrying gag gene HIV vaccine App 20030228329 - Chen, Ling ;   et al. | 2003-12-11 |
Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications App 20030044421 - Emini, Emilio A. ;   et al. | 2003-03-06 |
Gene therapy for stimulation of angiogenesis App 20020065240 - Thomas, Kenneth A. JR. ;   et al. | 2002-05-30 |
Adenovirus carrying gag gene HIV vaccine App 20020061517 - Chen, Ling ;   et al. | 2002-05-23 |
Gene therapy for inhibition of angiogenesis Grant 6,375,929 - Thomas, Jr. , et al. April 23, 2 | 2002-04-23 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.